[go: up one dir, main page]

WO2021104214A1 - Utilisation d'un exosome dérivé d'une carcasse dans un produit de régulation de la peau - Google Patents

Utilisation d'un exosome dérivé d'une carcasse dans un produit de régulation de la peau Download PDF

Info

Publication number
WO2021104214A1
WO2021104214A1 PCT/CN2020/130931 CN2020130931W WO2021104214A1 WO 2021104214 A1 WO2021104214 A1 WO 2021104214A1 CN 2020130931 W CN2020130931 W CN 2020130931W WO 2021104214 A1 WO2021104214 A1 WO 2021104214A1
Authority
WO
WIPO (PCT)
Prior art keywords
exosomes
skin
products
product
fetal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/130931
Other languages
English (en)
Chinese (zh)
Inventor
傅文燕
胡适
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharchoice Therapeutics Inc
Original Assignee
Pharchoice Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharchoice Therapeutics Inc filed Critical Pharchoice Therapeutics Inc
Publication of WO2021104214A1 publication Critical patent/WO2021104214A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/982—Reproductive organs; Embryos, Eggs
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/06—Products with modified nutritive value, e.g. with modified starch content
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/34—Animal material
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C15/00—Butter; Butter preparations; Making thereof
    • A23C15/12—Butter preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the technical field of biological skin conditioning products, and in particular relates to the use of exosomes derived from carcass in skin conditioning products and skin conditioning products containing the exosomes.
  • the descriptive literature does not describe the actual composition of sheep placenta. At present, most of the sheep placenta products on the market use physical and chemical means to break and crack the fetus, and then further obtain the protein and other molecules in it. On the one hand, its biological effects need to be further observed, which is generally considered to be more controversial. On the other hand, it is very different from the sheep fetal therapy described by Paul Nihan. Therefore, the active ingredients of sheep placenta are not clear, which has always been a scientific problem in the field.
  • exosome living cells can secrete a large number of exosomes (exosome), exosomes are endosomes that reverse budding to form multivesicular endosomes, and multivesicular endosomes fuse with cell membranes. Released outside the cell to form exosomes. Almost all cells can secrete exosomes.
  • the characteristics of these exosomes are: the diameter is between 30-150nm; the density is between 1.13-1.19g/mL; they express specific proteins and carry important signal molecules of the parent cell, including proteins, lipids and RNA, etc. ; Maintain the life activity similar to the parental cells. In particular, once the cell dies, the amount of exosomes secreted immediately decreases, indicating that exosomes are an active effector secreted by living cells.
  • Mammalian umbilical cord, placenta, etc. are important sources of exosomes. There have been many studies on extracting exosomes from mammalian umbilical cord or placenta and using them for skin conditioning, but animal fetuses have not been seen as the source of such exosomes. Research. In a small number of studies using animal carcass as a raw material for material extraction, the extracts are mostly concentrated in small molecular weight water-soluble molecules. For example, the patent document CN 103462864B discloses the separation of water-soluble molecules with a molecular weight of less than 4000D from the internal organs of animals. Used in cosmetics and food production.
  • patent document CN 103462865 B discloses the extraction and use of water extracts with molecular weights below 5000D from animal carcass skin and muscle. It is a water-soluble molecule with a molecular weight of less than 5000D, not an exosome.
  • the present invention was made to solve the above-mentioned technical problems, and aims to provide the use of exosomes derived from carcass in skin conditioning products, a method for preparing the exosomes, and skin conditioning products using the exosomes as active ingredients.
  • the first aspect of the present invention is to provide the use of carcass-derived exosomes in skin conditioning products.
  • the exosomes are exosomes extracted from the carcass of non-human viviparous animals, new internal organs or physiological fluids.
  • the fetus refers to larvae and new-born animals in the mothers of non-human viviparous animals, excluding fetal appendages.
  • sheep, cattle, deer and camels namely fetal sheep, fetal cattle, fetal deer and fetal camels
  • animal larvae are preferably fetal sheep at least 2 months old, fetal cattle at least 4 months old, fetal deer at least 3 months old, Fetal camels that are at least 6 months old
  • newborns refer to newborn animals within 24 hours of natural delivery.
  • the organs include lung, breast, stomach, pancreas, prostate, bladder, bone, ovary and accessories, uterus, skin, kidney, sinus, colon, rectum, esophagus, blood, brain and its covering, spinal cord and its covering , Muscle, connective tissue, adrenal gland, parathyroid, thyroid, testis, pituitary, genitals, liver, gallbladder, eyes, ears, nose, throat, tonsils, mouth, lymph nodes and lymphatic system and other organs; preferably liver, bone marrow.
  • the physiological fluid includes the following fluids: nasopharyngeal, oral cavity, esophagus, stomach, pancreas, liver, pleura, pericardium, peritoneum, intestine, prostate, semen, vaginal secretions, tears, saliva, mucus, bile, blood, lymph , Plasma, serum, synovial fluid, cerebrospinal fluid, uterine cavity and appendages, urine, and interstitial, intracellular and extracellular fluids; preferably blood, plasma and serum.
  • exosomes can promote cell proliferation, improve cell survival, promote cell ATP synthesis, increase mitochondrial activity, reduce inflammation and cell senescence, and increase the expression of some local targets. It is effective in aging. That is, in terms of application, the inventor found that exosomes have cosmetic and dermatological uses.
  • the cosmetic and dermatological uses include anti-aging, enhancing skin elasticity, fighting acne, strengthening hair follicles, and anti-hair loss.
  • the skin conditioning products of the present invention include direct application skin care products, oral skin conditioning products, or dermatological use products.
  • the direct application type skin care product is an anti-aging or skin elasticity skin care product
  • the oral skin conditioning product includes dairy products containing the exosomes, fat-based products, beverage products or cereal products
  • products for dermatological purposes are Dermatological products for fighting acne or strengthening hair follicles and anti-hair loss.
  • the anti-aging or skin elasticity skin care products are one or more combinations of skin care products that promote cell collagen expression, increase cell myofibril protein synthesis, maintain stem cell stemness, and stimulate stem cell proliferation; fight acne
  • the dermatological use products of keratinocytes are products that inhibit the gene expression of inflammatory mediators or matrix proteases in keratinocytes, and one or a combination of products that inhibit VEGF synthesis and release in keratinocytes; enhance hair follicles and anti-hair loss skin
  • the products for disease use are any one or two of products that promote ATP synthesis in hair follicle papillary fibroblasts or enhance mitochondrial metabolic activity, increase cell viability of microhair follicles, or reduce microhair follicle membrane damage.
  • the exosomes derived from the fetus of the present invention are intended to resist aging and promote healing by stimulating proliferation and maintaining the activity of stem cells. Therefore, the examples presented below show that exosomes have the following effects on human mesenchymal stem cells: increase the ratio of ALDH-positive cells and the expression of Ki67 ratio.
  • Exosomes specifically target the inflammatory process of acne that plays a central role in the development and aggravation of the disease. Therefore, the examples presented below show that exosomes have the following effects on keratinocytes:
  • Anti-inflammatory effect Inhibition of early mediators of inflammation (IL-1 ⁇ , IL-1 ⁇ ) and late mediators (IL-8); inhibition of keratinocyte-induced MMP (MMP-2 and MMP-9); inhibition of VEGF release effect.
  • Exosomes also have the following effects on P. acnes: inhibit P. acnes from inducing IL-8; inhibit P. acnes from inducing MMP-9.
  • topical or oral administration of the fetus-derived exosomes is used to maintain and/or increase the expression of type V collagen and/or myofibrin-1 and/or to increase the proliferation of hair follicle fibroblasts and/or It is used to increase cell viability and/or ATP synthesis and/or mitochondrial activity and/or reduce cell damage and/or reduce cell aging, and is used to strengthen hair follicles, thereby reducing the loss of skin appendages, such as hair loss.
  • the topical or oral administration of exosomes derived from the carcass of the present invention is used to increase the antioxidant enzymes NQO1 (Entrez Gene: 1728) and GSTT1 (Entrez Gene: 2952). Expression to eliminate and eliminate toxins; increase the expression of the natural immune factor skin antimicrobial peptide hBD3 (Entrez Gene: 55894) to achieve skin protection; and increase the antioxidant protein GPX1 (Entrez Gene: 2876) and catalase (catalase, Entrez Gene: 847), TRX1 (Entrez Gene: 7295) and PRDX1 (Entrez Gene: 5052) expression to inhibit the production of reactive oxygen species. Therefore, the composition can be used as a pharmaceutical composition or a cosmetic composition for preventing skin problems caused by Asian sand dust (PM2.5), protecting the skin, and preventing and treating skin aging.
  • PM2.5 Asian sand dust
  • the second aspect of the present invention is to provide a method for preparing carcass-derived exosomes, which are prepared by a method including the following steps:
  • the separation and purification of exosomes includes: centrifuging the culture solution or fluid at 4°C, 1000g for 10 minutes, and collecting the supernatant; collecting the supernatant at 4°C and centrifuging at 2000g for 20 minutes to collect the supernatant; and collecting the supernatant at 4°C Centrifuge at 10,000g for 30min to collect the supernatant; centrifuge the collected supernatant at 110,000g for 90min, discard the supernatant, and resuspend the pellet with phosphate buffer; centrifuge again at 110,000g for 90min, discard the supernatant, and resuspend the pellet with a small amount of phosphate buffer. Filtration with 0.45 ⁇ m filter membrane to obtain exosomes.
  • the exosomes prepared according to the above method have the following characteristics: a diameter of about 30-150 nm, a lipid membrane, and genetic materials such as protein, mRNA, and microRNA, etc. are encapsulated in the exosomes.
  • Protein analysis contains CD63, CD81, Alix and other protein molecules.
  • the third aspect of the present invention provides a composition containing exosomes as an active ingredient.
  • the composition contains at least one pharmaceutically acceptable excipient, especially cosmetically and dermatologically acceptable excipients.
  • the excipient may be an excipient suitable for topical application in vitro, or an excipient that can be applied to the human body.
  • formulations are suitable for topical application, and include creams, gels, emulsifiers, emulsions, ointments, lotions, oils, aqueous solutions or hydrogen-alcohol or glycolic acid solutions, Powder, patch, spray or any other product for external application.
  • Such formulations are presented in the examples below.
  • various formulations are suitable for oral administration, wherein the exosomes can be included in a dietary supplement or dietary composition.
  • dietary supplements can be provided in the form of hard or soft gelatin or vegetable capsules.
  • the dietary supplement may thus contain 1% to 100% exosomes by weight.
  • exosomes of the present invention can also be incorporated into dietary compositions such as foods, beverages and nutraceuticals, and the dietary compositions include the following products:
  • Dairy products such as cheese, butter, milk and other milky beverages, mixtures and pastes containing milk products, ice cream and yogurt;
  • Fat-based products such as margarine, pasty food, mayonnaise, cooking fat, frying oil and vinaigrette;
  • Cereal-based products composed of grains, such as bread and pasta products, regardless of whether these foods have been cooked, baked or processed;
  • Candies such as chocolate, confectionery, chewing gum, desserts, toppings, refreshing fruit drinks (sorbet), cake icing and other garnishes;
  • Alcoholic or non-alcoholic beverages including soda and other soft drinks, juices, dietary supplements, meal substitutes in the form of beverages such as those sold under the brand names Boost TM and Ensure TM, and;
  • exosomes can be incorporated into food, nutraceuticals, dietary products, especially high-protein products or beverages directly with the help of techniques such as mixing, infusion, injection, blending, adsorption, kneading and spraying without other modifications.
  • the fourth aspect of the present invention also relates to a method for the cosmetic treatment of acne, which is characterized in that the composition of the present invention is applied to a diseased skin area or a diseased individual orally takes the nutraceutical composition of the present invention.
  • the present invention may also relate to the use of exosomes for the preparation of cosmetics, nutraceuticals or dermatological compositions for the treatment or prevention of acne.
  • composition will preferably be formulated in a formulation suitable for topical application.
  • composition in the context of use in food, for nutritional or cosmetic purposes (cosmetic food), the composition will preferably be formulated in a formulation suitable for oral administration.
  • the cosmetic care method of the present invention includes topical application of the exosomes of the present invention or a composition containing the same to all or part of the body selected from the group consisting of legs, feet, armpits, hands, thighs, abdomen, neckline, The neck, arms, trunk, back, face, skin appendages, preferably hair, and/or scalp, more advantageously the scalp.
  • composition of the present invention may also contain at least one pharmaceutical adjuvant known to those skilled in the art, such as thickeners, preservatives, fragrances, colorants, chemical or mineral sunscreens, wetting agents, and hot spring water. Wait.
  • pharmaceutical adjuvant known to those skilled in the art, such as thickeners, preservatives, fragrances, colorants, chemical or mineral sunscreens, wetting agents, and hot spring water. Wait.
  • composition of the present invention may also comprise a sebum regulator, antibacterial agent, antifungal agent, keratolytic agent, stratum corneum regulator, astringent, anti-inflammatory/anti-irritant, antioxidant/radical scavenger, At least one anti-aging compound of scarring agent, anti-aging agent and/or wetting agent.
  • sodium regulator refers, for example, to 5- ⁇ -reductase inhibitors, such as active substances Zinc and its gluconate, salicylate and pyroglutamic acid also have sebum inhibitory activity. Mention can also be made of spironolactone, an antiandrogen and aldosterone antagonist, which significantly reduces the rate of sebum secretion after 12 weeks of application. Other extracted molecules (such as seeds from Cucurbita pepo, pumpkin seed oil, and palm cabbage) limit sebum production by inhibiting 5- ⁇ -reductase transcription and activity. Other lipid-derived sebum regulators that affect the properties of sebum, such as linoleic acid, can also be used.
  • antibacterial agent and “antifungal agent” refer to molecules that restrict the growth of or destroy pathogenic microorganisms such as certain bacteria such as Propionibacterium acnes or certain fungi (Malassezia furfur).
  • preservatives commonly used in cosmetics or nutraceuticals, that is, molecules with antibacterial activity (pseudopreservatives) such as caprylic acid derivatives (caprylylglycine, caprylic glyceride, etc.), such as hexylene glycol and sodium levulinate , Zinc and copper derivatives (gluconate and PCA), phytosphingosine and its derivatives, benzoyl peroxide, piroctone ethanolamine, zinc pyrithione, selenium disulfide, econazole, ketone Conazole, or topical antibiotics such as erythromycin and clindamycin.
  • stratum corneum regulator and “keratolytic agent” refer to substances that regulate or assist the elimination of dead cells in the epidermal stratum corneum.
  • Commonly used stratum corneum regulators/stratum corneum separation agents include: fruit alpha-hydroxy acid (AHAS) (citric acid, glycolic acid, malic acid, lactic acid, etc.) ), the combination of AHA ester, AHAS and other molecules such as the combination of malic acid and marzipan
  • AHAS fruit alpha-hydroxy acid
  • AHA ester AHAS and other molecules
  • glycolic acid or lactic acid and arginine or hydroxy acid and lipid molecules such as (Lipo-hydroxy acid) combination, amphoteric hydroxy acid complex (AHCare), willow bark (white willow bark extract), azelaic acid and its salts and esters, salicylic acid and its derivatives such as caprylyl salicylic acid Or in combination with other molecules such as salicylic acid and polysaccharides ( ⁇
  • astringent refers to substances that help narrow pores. The most commonly used are polyphenols, zinc derivatives, and North American witch hazel.
  • anti-inflammatory/anti-irritant refers to a substance that limits the inflammatory response caused by cytokines or arachidonic acid metabolism mediators and has smooth and anti-irritant properties.
  • the most common are glycyrrhetinic acid (glycyrrhizin derivatives) and its salts and esters, ⁇ -bisabolol, Ginkgo biloba, Calendula, lipoic acid, ⁇ -carotene, vitamin B3 (niacinamide) Nicolamide), vitamin E, vitamin C, vitamin B12, flavonoids (green tea, quercetin, etc.), lycopene or lutein, avocado sugar, avocado oleodistillate, arabic gal Glycan, lupin peptide, total lupin extract, quinoa peptide extract, circulating ceramide (Oxazoline derivatives), anti-glycation agents such as carnosine, N-acetylcysteine, isoflavones
  • Antioxidant refers to molecules that reduce or prevent the oxidation of other chemicals.
  • Antioxidant/radical scavengers that can be used in combination are preferably selected from the group consisting of mercaptans and phenols, licorice derivatives such as glycyrrhetinic acid and its salts and esters, ⁇ -bisabolol, ginkgo extract, marigold Flower (Calendula) extract, circulating ceramide (Oxazoline derivatives), avocado peptides, trace elements such as copper, zinc and selenium, lipoic acid, vitamin B12, vitamin B3 (niacinamide, nicotiamide), vitamin C, vitamin E, coenzyme Q10, krill oil (krill), glutathione, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), lycopene or lutein, ⁇ -carotene, polyphenol family such as tannins, phenolic acids
  • the antioxidant group also includes anti-glycation agents such as carnosine or certain peptides, N-acetylcysteine, and antioxidant or free radical scavenging enzymes, such as superoxide dismutase (SOD), catalase, glutathione Peroxidase, thioredoxin reductase and its antagonists.
  • anti-glycation agents such as carnosine or certain peptides, N-acetylcysteine, and antioxidant or free radical scavenging enzymes, such as superoxide dismutase (SOD), catalase, glutathione Peroxidase, thioredoxin reductase and its antagonists.
  • SOD superoxide dismutase
  • catalase glutathione Peroxidase
  • thioredoxin reductase and its antagonists.
  • the substance that can be used in combination to generate scars/repair barrier function is preferably vitamin A, panthenol (vitamin B5), avocado furan Lupin, Macatide Extract, Quinoa Peptide Extract, Arabinogalactan, Zinc Oxide, Magnesium, Silicon, Asiatic Acid or Asiatic Acid, Dextran Sulfate, Coenzyme Q10, Glucosamine And its derivatives, chondroitin sulfate and total glycosaminoglycans (GAGs), dextran sulfate, ceramide, cholesterol, squalane, phospholipids, fermented or unfermented soybean peptides, plant peptides, marine polysaccharides, plants Polysaccharides or biotechnological polysaccharides, such as algae extracts or fern extracts, trace elements, tannin-rich plant extracts such as tannins derived from gallic acid, which are called gallic tannins or hydrolyzable tannins, It was originally found in oak gall, and
  • Anti-aging agents that can be used in combination to treat acne in mature subjects are antioxidants, especially vitamin C, vitamin A, retinol, retinal, hyaluronic acid of any molecular weight, avocado furan Lupin peptide and maca peptide extract.
  • humectants/emollients are glycerin or its derivatives, urea, pyrrolidone carboxylic acid and its derivatives, hyaluronic acid of any molecular weight, glycosaminoglycans and those of marine, plant or biotechnological origin Any other polysaccharides, such as xanthan gum, Certain fatty acids such as lauric acid, myristic acid, monounsaturated and polyunsaturated omega-3, -6, -7 and -9 fatty acids (linoleic acid, palmitoleic acid, etc.), sunflower oleodistillate , Avocado peptides and cupuacu butter.
  • the combination of the present invention includes a composition comprising exosomes and plant and animal unsaponifiables, for example, avocado and soybean unsaponifiables and unsaponifiable vegetable oils or animal oil concentrates
  • unsaponifiables for example, avocado and soybean unsaponifiables and unsaponifiable vegetable oils or animal oil concentrates
  • sunflower oil or palm oil concentrate or vegetable oils containing unsaponifiables, such as soybean oil and rapeseed oil, and derivatives of unsaponifiables such as avocado furan, sterol esters, and vitamin derivatives.
  • the combination of the present invention includes a composition comprising exosomes and avocado sugar (see application WO2005/115421).
  • the composition is particularly suitable for the treatment of skin barrier repair and inflammation.
  • the combination of the present invention includes a composition comprising exosomes and avocado peptides (see International Application WO2005/105123).
  • the composition is particularly suitable for treating irritation and inflammation.
  • the combination of the present invention includes a composition comprising exosomes and avocado oil (see international applications WO2004/012496, WO2004/012752, WO2004/016106, WO2007/057439).
  • the combination of the present invention includes a composition comprising exosomes and avocado furan (Avocado furan, which can be obtained by the method described in the international application WO01/21605).
  • the composition is particularly suitable for treating inflammation, promoting scar formation and suitable for its anti-aging properties.
  • the combination of the present invention includes a composition comprising exosomes and avocado and soy unsaponifiables.
  • the avocado and soybean unsaponifiables that can be used in combination are preferably a mixture of avocado furanic unsaponifiables and soybean unsaponifiables in a ratio of about 1:3-2:3, respectively.
  • the combination of the present invention includes a composition comprising exosomes and lupeol (FR2822821, FR2857596).
  • the composition is particularly suitable for supporting scar formation.
  • the combination of the present invention includes a composition comprising exosomes and lupin peptides, such as lupin peptides obtained according to the method described in application WO2005/102259.
  • the composition is particularly suitable for treating inflammation and is used because of its anti-aging properties.
  • the combination of the present invention includes a composition comprising exosomes and total lupin extract (see International Application WO2005/102259).
  • the composition is particularly suitable for treating irritation.
  • the combination of the present invention includes a composition comprising exosomes and lupin oil, preferably sweet white lupin oil, as described in the international application WO98/47479 White lupin oil.
  • the combination of the present invention includes a composition comprising exosomes and a maca peptide extract (see International Application WO2004/112742).
  • the composition is particularly preferred due to its scarring properties and anti-aging properties.
  • the combination of the present invention includes a composition comprising exosomes and rice peptides (see International Application 2008/009709).
  • the composition is particularly preferred due to its properties related to the stimulation of melanin formation and the transfer of melanin.
  • the combination of the present invention includes a composition comprising exosomes and circulating ceramide (Oxazoline derivatives), as described in international applications WO2004/050052, WO2004/050079 and WO2004/112741.
  • the composition is particularly suitable for the treatment of inflammatory reactions.
  • the combination of the present invention includes a composition comprising exosomes and quinoa extract, especially peptide extract (see International Application WO2008/080974).
  • the composition is particularly suitable for the treatment of inflammatory diseases and skin barrier repair.
  • the combination of the present invention includes a composition comprising exosomes and cupuacu butter.
  • the composition is particularly preferred because of its wetting properties.
  • the combination of the present invention includes a composition comprising exosomes and rapeseed oil essence (rapeseed oleodistillate).
  • the combination of the present invention includes a composition comprising exosomes and corn oleodistillate.
  • all of these combinations contain at least one other active compound, and may contain two, three, four or more active compounds as described above.
  • the exosomes of the present invention can be combined with sunscreen active substances known to those skilled in the art such as UVB and/or UVA filters or shades or Any inorganic and/or organic light-shielding material or filter is used in combination, and the skilled person will adjust their selection and concentration according to the degree of protection sought.
  • sunscreen active substances known to those skilled in the art such as UVB and/or UVA filters or shades or Any inorganic and/or organic light-shielding material or filter is used in combination, and the skilled person will adjust their selection and concentration according to the degree of protection sought.
  • sunscreen active substances titanium dioxide, zinc oxide, methylene bis-benzotriazole tetramethyl butyl phenol (brand name: TIINOORB M) and bis-ethylhexyloxyphenol methoxybenzene can be specifically mentioned.
  • Triazine brand name: TINOSORB S
  • octyl-salicylic acid butylmethoxydibenzoylmethane
  • terephthalmethylene dicamphorsulfonic acid 4-methylbenzylidene camphor
  • benzophenone Ethylhexyl methoxycinnamate
  • aging and the term “skin aging” are used to describe visible changes in the appearance of the skin and those visible changes that can be detected by touch, such as wrinkles, fine lines, and wrinkles in a non-limiting sense.
  • Roughness, expression lines, stretch marks, discontinuities, deep wrinkles, sagging, sagging skin (such as sagging cheeks, eye bags, double chin), increase in pore size, loss of elasticity, loss of resilience, loss of firmness, elastic tissue degeneration , Abnormal differentiation, hyperkeratosis, keratosis, skin color changes (such as spots, redness, or bags under the eyes), formation of hyperpigmented areas (such as age spots, melasma, or freckles), loss of smoothness, orange peel Skin-like skin, loss of collagen structure and other histological changes in the stratum corneum, dermis, epidermis, vascular system (such as the formation of spider veins or telangiectasia), or these tissues near the skin.
  • Skin aging is a process with two main parts.
  • the two main parts are: temporal aging, which is attributed to the passage of time; and light-induced aging, which is attributed to the level of exposure to ultraviolet radiation and is called light Ageing.
  • the sum of several environmental factors such as exposure to tobacco smoke, exposure to pollution, and climatic conditions (such as cold and/or wind) also contribute to skin aging.
  • skin anti-aging treatment is a treatment for preventing, delaying, and/or reducing the aging of human skin.
  • the present invention provides the use of carcass-derived exosomes in skin conditioning products.
  • the exosomes can promote cell collagen expression, increase cell myofibrillar protein synthesis, maintain stem cell stemness, and stimulate stem cells. Proliferation to achieve anti-aging function; products that can inhibit inflammatory mediators or matrix protease gene expression in keratinocytes, and inhibit the synthesis and release of VEGF in keratinocytes to achieve pharmaceutical functions against acne; can promote hair follicle papillary fibroblasts ATP synthesis or products that enhance the metabolic activity of mitochondria, increase the cell viability of the microhair follicles or reduce the damage of the microhair follicle membrane, realize the dermatological use of enhancing hair follicles and anti-hair loss; it can achieve clearance and elimination by increasing the expression of antioxidant enzymes NQO1 and GSTT1 Eliminate toxins; increase the expression of the skin antimicrobial peptide hBD3, which is a natural immune factor, to protect the skin; and increase the
  • the present invention provides a new approach for skin care such as anti-aging skin care, acne fighting, anti-hair loss, and anti-Asian dust effects.
  • Figure 1 is the electron microscope detection result of the exosomes derived from the carcass of the present invention
  • Figure 2 shows the results of the particle size distribution of exosomes detected by NTA.
  • the comparison statistics between multiple groups uses analysis of variance and between-group tests to calculate the P value.
  • the non-parametric T test is used to calculate the P value.
  • the comparison of multiple rates uses the chi-square test to calculate the P value. .
  • the 4-month-old Alpine black sheep fetal serum was filtered with a 0.45 ⁇ m filter, centrifuged at 4°C, 1000g for 10min, and the supernatant was collected; the collected supernatant was centrifuged at 4°C, 2000g for 20min, and the supernatant was collected; the collected supernatant Centrifuge the supernatant at 10,000g for 30min at 4°C, and collect the supernatant; centrifuge the collected supernatant at 110,000g for 90min, discard the supernatant, and resuspend the pellet in phosphate buffer; centrifuge again at 110,000g for 90min, discard the supernatant, and resuspend in a small amount of phosphate buffer.
  • exosomes Precipitate, filter with 0.45 ⁇ m filter membrane to obtain exosomes.
  • the Bradford method was used to detect the total protein content of exosomes (Bio-Rad Protein Assay Reagent).
  • the exosomes were lyophilized and stored at -80°C.
  • Adult goat serum was used to extract exosomes in the same way as control exosomes.
  • the 11-month-old Australian alpaca serum was filtered with a 0.45 ⁇ m filter, centrifuged at 4°C, 1000g for 10min, and collected the supernatant; the collected supernatant was centrifuged at 4°C, 2000g for 20min, and the supernatant was collected; the collected supernatant was 4°C Centrifuge at 10,000g for 30min to collect the supernatant; centrifuge the collected supernatant at 110,000g for 90min, discard the supernatant, and resuspend the pellet with phosphate buffer; centrifuge again at 110,000g for 90min, discard the supernatant, and resuspend the pellet with a small amount of phosphate buffer.
  • exosomes were lyophilized and stored at -80°C.
  • Adult alpaca serum was used to extract exosomes in the same way as control exosomes.
  • the 8-month-old Australian fetal bovine serum was filtered with a 0.22 ⁇ m sterile membrane, centrifuged at 4°C, 1000g for 10min, and the supernatant was collected; the collected supernatant was centrifuged at 4°C, 2000g for 20min, and the supernatant was collected; the collected supernatant 4 Centrifuge the supernatant at 10,000g for 30min at °C, and collect the supernatant; centrifuge the collected supernatant at 110,000g for 90min, discard the supernatant, and resuspend the pellet with phosphate buffer; centrifuge again at 110,000g for 90min, discard the supernatant, and resuspend the pellet with a small amount of phosphate buffer , 0.45 ⁇ m filter membrane to obtain exosomes.
  • the Bradford method was used to detect the total protein content of exosomes (Bio-Rad Protein Assay Reagent). The exosomes were lyophilized and stored at -80
  • the liver of 4-month-old alpine black sheep fetal sheep was washed repeatedly with phosphate buffered saline (PBS) and cut into tissue pieces with a diameter of about 1-2 mm; after digestion with type 2 collagenase and trypsin, the supernatant was centrifuged Put the cell pellet into a culture flask, and use DMEM/F12 medium containing 10% fetal bovine serum, 5% CO 2 , 37°C saturated humidity; remove non-adherent cells, and replace with no serum after 80% of adherent cells are fused
  • the culture medium was cultured for 48 hours; the culture supernatant was collected; the culture solution rich in exosomes was obtained by filtering with a 0.45 ⁇ m filter membrane.
  • the particle size detection method of exosomes derived from fetal sheep serum obtained in Example 1 by NanoFCM Flow NanoAnalyzer includes the following steps:
  • Particle size detection The particle size standard, blank control and sample (uterine cavity fluid) need to be sampled under the same detection conditions (laser power and attenuation coefficient of the scattering channel are exactly the same); all samples are under lower injection pressure (Sampling is not more than 1.0kPa) detection; under appropriate conditions, detect the particle size standard (the scattered light signal of the smallest particle size silicon ball is completely separated from the background and the largest silicon ball signal is not saturated, and the detector saturation value is 3.6k ); Detection of the buffer used to resuspend the sample to be tested, used to deduct background particles, as a blank control; to detect the sample to be tested, if the signal intensity of more than 20% of the particles in the sample to be tested reaches saturation in the scattering channel, it indicates that the current The particle size standard product is not the best choice for the particle size characterization of the sample; after the above steps, it is detected that most of the particle size in the sample is around 85nm, which is in the range of 30-150nm in exosomal diameter
  • the fetal goat serum exosomes (0.02% mass-volume ratio) described in Example 1 were added to the culture medium (DMEM medium, 1% antibiotics) of human fibroblasts to confirm that the exosomes promote 1 at the cellular level.
  • Type collagen synthesis The synthetic collagen was measured using the PICP kit (Procollagen Type I C Peptidase Immunoassay Kit) for quantification.
  • human fibroblast culture medium human fibroblasts (human fibroblast) were divided into 6-well plates at 2 ⁇ 10 5 cells/well. After confirming cell adhesion, fetal goat serum exosomes as the active ingredient were dissolved in the culture medium.
  • the control group used adult goat serum exosomes with the same concentration.
  • the blank group did not add any exosomes, only the culture medium. After culturing for 24 hours in an incubator at 37°C and 5% CO2, the content of type I collagen in the cell lysate was determined. The results are shown in Table 1. The results show that fetal goat serum exosomes can promote collagen expression .
  • Example 7 The effect of exosomes on artificial skin
  • This example was performed using the fetal camel serum exosomes and control exosomes described in Example 2.
  • EFT-400 fetal sheep serum exosomes described in Example 1 at a concentration of 0.02% (mass volume ratio) was applied as an active ingredient.
  • Exosomes containing 1% serum from adult goats were used as a control (control). No exosomes were added to the blank group, only culture medium.
  • Example 8 Exosomes enhance the expression of ALDH in mesenchymal stem cells.
  • This example was performed using the fetal goat serum exosomes and control exosomes described in Example 1.
  • the mesenchymal stem cells (MSC) derived from human bone marrow were divided into 6-well plates at 2 ⁇ 10 5 cells/well. After confirming cell adhesion, fetal goat serum exosomes as the active ingredient were dissolved in culture medium. Adult goat serum exosomes were used in the control group, and the concentration of exosomes in each well was 200 ⁇ g/ml. No exosomes were added to the blank group, only culture medium. After culturing in an incubator at 37°C and 5% CO 2 for 24 hours, flow cytometry was used to detect the ALDH positive rate and Ki67 positive rate of MSC cells. The results are shown in Table 4.
  • Example 9 The effect of exosomes on the prevention and treatment of acne
  • Table 8 Analysis of IL-8 in keratinocytes/P. acnes co-culture
  • MMP-9 plays a particularly important role.
  • this protease is positively regulated by pro-inflammatory cytokines and also positively regulated by P. acnes.
  • Table 11 MMP-9 gene expression in keratinocyte/P. acnes co-culture
  • PMA stimulates keratinocytes for 24 hours to induce a large and significant release of VEGF (+226%).
  • pretreatment of keratinocytes with exosomes for 24 hours had this effect and significantly inhibited this effect.
  • the stomach of a 3-month-old fetal pig was washed repeatedly with phosphate buffered saline (PBS) and cut into tissue pieces with a diameter of about 1-2mm; after digestion with type 2 collagenase and trypsin, the supernatant was centrifuged and the cells were collected Put the precipitate in a culture flask, use DMEM/F12 medium containing 10% fetal bovine serum, 5% CO 2 , 37°C saturated humidity; remove non-adherent cells, replace the serum-free medium after the adherent cells are 80% fused 48h; collect the culture supernatant; filter with a 0.45 ⁇ m filter membrane to obtain a culture solution rich in exosomes.
  • PBS phosphate buffered saline
  • the fetal gastric juice of newborn black sheep was filtered with a 0.45 ⁇ m filter, centrifuged at 4°C, 1000g for 10min, and the supernatant was collected; the collected supernatant was centrifuged at 4°C, 2000g for 20min, and the supernatant was collected; the collected supernatant was 4°C, 10000g Centrifuge for 30 min, collect the supernatant; centrifuge the collected supernatant at 110,000 g for 90 min, discard the supernatant, and resuspend the pellet in phosphate buffer; centrifuge again at 110,000 g for 90 min, discard the supernatant, and resuspend the pellet in a small amount of phosphate buffer, 0.45 ⁇ m Filter membrane to obtain exosomes.
  • the Bradford method was used to detect the total protein content of exosomes (Bio-Rad Protein Assay Reagent). The exosomes were lyophilized and stored at -80°C.
  • Example 1 The fetal sheep serum exosomes described in Example 1 and the fetal sheep liver exosomes described in Example 4 were used for this example.
  • the exosomes increased the expression of type V collagen by at least 22% and 35%, showing the properties of exosomes in enhancing the expression of collagen, which can be used to strengthen hair follicles and reduce The nature of hair loss.
  • Example 14 Exosomes promote increased ATP synthesis in hair follicle papilla fibroblasts
  • Non-pathological human fibroblasts from hair follicle papilla were cultured on DMEM medium for 24 hours, and then treated with the fetal goat serum exosomes described in Example 1 and the fetal camel serum exosomes described in Example 2 6 On days, the final concentration/volume is 0.02% or 0.05% by volume relative to the total volume of the culture medium. After 6 days, the ATP content was measured by enzymatic method (luciferin/luciferase complex; ATP Bioluminescence kit Roche Diagnostics) (Table 15).
  • the fetal camel serum exosomes described in Example 2 0.02% (w/v medium) 135 15.95 p ⁇ 0.05
  • the fetal camel serum exosomes described in Example 2 0.05% (w/v medium) 157 20.33 p ⁇ 0.01
  • Example 15 Exosomes enhance the mitochondrial metabolic activity of dermal papilla fibroblasts
  • the non-pathological human fibroblasts from the hair follicle papilla were cultured for 24 hours, and the fetal goat serum exosomes described in Example 1 and the fetal camel serum exosomes described in Example 2 were treated for 6 days.
  • the total volume of the medium is 0.02% and 0.05%.
  • MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
  • the resulting precipitate was extracted with DMSO, and then the optical density of the DMSO solution was measured at 540 nm (Table 16).
  • the exosomes of the present invention show increased mitochondrial activity of hair follicle papilla fibroblasts. This mitochondrial activity participates in the enhancement of hair follicles.
  • Example 16 The effect of exosomes on microhair follicles
  • the micro hair follicle model includes papillary fibroblasts, keratinocytes from the outer sheath of hair follicles and melanocytes co-cultured in three dimensions. Due to the ability to integrate the neuro-epidermal-mesenchymal interactions between various cell types, this cell model constitutes the closest reconstructed organ model to hair follicles.
  • Non-pathological papillary fibroblasts were cultured for 3 days. Then, melanocytes and keratinocytes of the outer sheath of hair follicles are added to the new type of papilla to form micro hair follicles. After culturing for 24 hours, the fetal goat serum exosomes described in Example 1 were added, and the final concentration was 0.05% by volume relative to the total volume of the culture medium. The same medium was cultured in the case of adult goat serum exosomes (control). After 48 hours of treatment, the culture medium and microfollicles were sampled for analysis.
  • the cell viability of microhair follicles was measured by the PrestoBlue method (Thermo Fisher Scientific). The measurement is carried out after 48 hours of treatment. The value is expressed as the mean% of the normalized control (Table 17).
  • the exosomes of the present invention have the ability to increase the cell viability of microhair follicles, making them active exosomes for enhancing hair follicles.
  • lactate dehydrogenase detection method cell damage is measured by a colorimetric method, so that cell damage can be quantified based on the measurement of lactate dehydrogenase activity in damaged cells in the culture medium. Increased cell membrane damage and cell lysis lead to an increase in lactate dehydrogenase activity, which is proportional to the number of lysed cells. After 48 hours of treatment, lactate dehydrogenase activity was measured in the culture medium (Table 18).
  • the exosomes of the present invention have the ability to reduce membrane damage, making them the exosomes of the present invention that are active in enhancing hair follicles, and enhancing hair follicles promotes the reduction of hair loss.
  • Example 17 Exosomes respond to the production of reactive oxygen species in human keratinocytes caused by Asian dust
  • Asian dust is a climatic phenomenon that originated in the deserts of my country, Mongolia, Central Asia and Russia. In these places, sand or yellow dust blows eastward with the wind and falls to the ground. Almost every spring, Beijing and other northern regions are affected by Asian dust.
  • Asian dust contains organic and inorganic substances, and their physical properties and composition are different. It even contains metals that may have biological effects.
  • the large particles contained in the Asian dust remain in or around the place, while the particles with a diameter of 10 ⁇ m or less (particulate matter 10; PM10), the continuous outbreak of PM2.5 in recent years also belong to this type of climate pollution.
  • Asian dust storms are known to cause dry skin, keratinization, itching, acne, atopy, etc. by depriving the skin of moisture.
  • Asian dust causes an increase in keratinocytes including the cytokines interleukin 6 and interleukin 8 pro-inflammatory factors (Choi et al,. Toxicol Lett. 15; 200(1-2): 92 -9.2010).
  • Human epidermal neonatal keratinocyte cells were cultured for 24 hours under the same culture conditions as those described in the Lonza company's instructions. The cells were then treated with the fetal goat serum exosomes described in Example 1 and the fetal camel serum exosomes described in Example 2 for 12 hours, and the final concentration/volume was 0.02% or 0.05% volume relative to the total volume of the culture medium. , And then add 25 ⁇ g/mL Asian sand dust sample, and incubate each group of cells for 24 hours. The Asian dust samples were collected on the balcony roof of Tower A of China World Trade Center Phase III (Beijing) during the Asian dust season.
  • Beijing China World Trade Center Phase III
  • Example 18 Expression of Exosomes on Toxin Detoxification and Elimination Factors and Antimicrobial Peptides
  • Example 17 the human epidermal keratinocyte cells were cultured for 24 hours, and the culture conditions were the same as those described in the instructions of Lonza Company. The cells were then treated with the fetal goat serum exosomes described in Example 1 and the fetal camel serum exosomes described in Example 2 for 12 hours, and the final concentration/volume was 0.02% and 0.05% volume relative to the total volume of the culture medium. , And then add 25 ⁇ g/mL Asian sand dust sample, and incubate each group of cells for 24 hours. The Asian dust samples were collected on the balcony roof of Tower A of China World Trade Center Phase III (Beijing) during the Asian dust season.
  • Beijing China World Trade Center Phase III
  • RNA kit Qiagen
  • RT Superscript reverse transcriptase II kit
  • qPCR real-time reverse transcription polymerase chain reaction
  • the fetal camel serum exosomes described in Example 2 0.02% (w/v medium) 331.97 33.29 p ⁇ 0.05
  • the fetal camel serum exosomes described in Example 2 0.05% (w/v medium) 743.04 97.00 p ⁇ 0.05
  • the results show that the extrafetal body of the present invention can increase the expression of detoxified protein NQO1, skin antimicrobial peptide hBD3 of natural immune factors, and GSTT1 of detoxifying enzyme in normal human keratinocytes.
  • Example 17 the human epidermal keratinocyte cells were cultured for 24 hours, and the culture conditions were the same as those described in the instructions of Lonza Company. The cells were then treated with the fetal goat serum exosomes described in Example 1 and the fetal camel serum exosomes described in Example 2 for 12 hours, and the final concentration/volume was 0.02% and 0.05% volume relative to the total volume of the culture medium. , And then add 25 ⁇ g/mL Asian sand dust sample, and incubate each group of cells for 24 hours. The Asian dust samples were collected on the balcony roof of Tower A of China World Trade Center Phase III (Beijing) during the Asian dust season.
  • Beijing China World Trade Center Phase III
  • RNA kit Qiagen
  • RT Superscript reverse transcriptase II kit
  • qPCR real-time reverse transcription polymerase chain reaction
  • TaqMan gene expression assay kit (TaqMan gene expression assay kit, A plied Biosystems) to detect the expression levels of GPX1 (Hs00829989_gH), catalase (Hs00156308_m1), TRX1 (Hs01555212_g1) and PRDX1 (Hs00602020_mH), and the results are shown in the table .
  • the fetal sheep serum exosomes described in Example 1 of the present invention are 1.2%, butanediol 5%, preservative 0.2% and 0.6% sodium chloride, water 93%, and weigh the appropriate amount of each raw material group. Minute.
  • the above-mentioned raw material components are mixed to obtain anti-aging skin care water.
  • Volunteers apply the anti-aging cosmetics of the present invention once a day in the morning and evening, and wash their face with clean water after 30 minutes of each application. The use period is 4 weeks, and no other cosmetics are allowed to be used during the test period. Then, the skin elasticity tester and the facial wrinkle imager were used to compare and analyze the improvement of the volunteers' skin elasticity and wrinkles by the anti-aging cosmetics of the present invention. The results are as follows:
  • Example 21 Examples of cosmetic preparations
  • compositions for topical application especially for cosmetics.
  • Nylon 6 0%-2% Polyacrylamide gel 1%-5% Vitamin B6 0%-1% spices 0%-1% Pure water QSP100%
  • Raw material/brand name % castor oil QSP 100% Oleyl alcohol 10%-20% Palm oil 10%-20% Polyglycerol-3-beeswax 10%-20% Candelilla wax 10%-20% Hectorite 10%-20% Titanium dioxide 0%-5% Fetal Sheep Serum Exosomes 0.01%-0.1% Seborin 0%-5% Vitamin E 0%-1%

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation d'un exosome dérivé d'une carcasse dans un produit de régulation de la peau. Des expériences prouvent que l'exosome assure une fonction anti-âge au moyen de la promotion de la production de collagène cellulaire, etc. ; l'exosome assure la fonction pharmaceutique de résistance à l'acné au moyen de l'inhibition de médiateurs inflammatoires dans les kératinocytes, etc. ; l'exosome assure les utilisations dermatologiques d'amélioration des follicules pileux et de prévention de la chute de cheveux au moyen de la promotion de la synthèse d'ATP dans les fibroblastes de la papille dermique des follicules pileux, etc ; et l'exosome évite les problèmes cutanés provoqués par les tempêtes de sable asiatiques au moyen de l'inhibition de la production d'oxygène actif, etc.
PCT/CN2020/130931 2019-11-27 2020-11-23 Utilisation d'un exosome dérivé d'une carcasse dans un produit de régulation de la peau Ceased WO2021104214A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911179142.8A CN110840812A (zh) 2019-11-27 2019-11-27 胎体来源的外泌体在皮肤调节产品中的用途
CN201911179142.8 2019-11-27

Publications (1)

Publication Number Publication Date
WO2021104214A1 true WO2021104214A1 (fr) 2021-06-03

Family

ID=69605022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/130931 Ceased WO2021104214A1 (fr) 2019-11-27 2020-11-23 Utilisation d'un exosome dérivé d'une carcasse dans un produit de régulation de la peau

Country Status (2)

Country Link
CN (1) CN110840812A (fr)
WO (1) WO2021104214A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307851A (zh) * 2021-06-11 2021-08-27 北京戴域生物技术有限公司 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840812A (zh) * 2019-11-27 2020-02-28 沣潮医药科技（上海）有限公司 胎体来源的外泌体在皮肤调节产品中的用途
CN111690600A (zh) * 2020-04-16 2020-09-22 艾一生命科技(广东)有限公司 一种工程化人脐带间充质干细胞外泌体及透皮制剂与应用
CN114748504A (zh) * 2020-12-29 2022-07-15 南京优智源医药科技有限公司 年轻人血浆外泌体在制备治疗衰老引发的退行性疾病的药物中的应用
CN113943700B (zh) * 2021-10-21 2023-10-27 艾一生命科技(广东)有限公司 一种牛血清外泌体用于干细胞培养的方法
CN114045259B (zh) * 2021-11-08 2024-04-05 山东第一医科大学(山东省医学科学院) 一种抑制肿瘤干细胞的方法
CN114159374A (zh) * 2021-12-10 2022-03-11 上海纳米技术及应用国家工程研究中心有限公司 用于皮肤抗衰老间充质干细胞外泌体组合物的制备方法及产品和应用
CN115537374B (zh) * 2022-09-23 2024-08-20 杭州昱鼎生物科技有限公司 一种体液中提取外泌体的钠基蒙脱石（Na-MMT）吸附柱法
CN115778892A (zh) * 2022-12-30 2023-03-14 广州赛莱拉生物基因工程有限公司 含有（动物）脐带提取物的头皮护理组合物及头皮护理产品
CN116115547A (zh) * 2023-02-09 2023-05-16 深圳市沃英达生命科学有限公司 一种含有牛胎盘组织来源外泌体的祛斑组合物及其应用
CN117024557B (zh) * 2023-10-10 2024-01-30 天津外泌体科技有限公司 14-3-3蛋白theta异构体作为细胞外囊泡支架蛋白的应用和细胞外囊泡
CN117100673B (zh) * 2023-10-23 2024-02-23 广州优特佳生物科技发展有限公司 一种调节毛囊周期的动物脐带提取物及其制备方法和应用
CN119823941B (zh) * 2025-03-18 2025-07-08 博雅干细胞科技有限公司细胞科技分公司 一种间充质干细胞外泌体的制备方法及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267240A (zh) * 2014-12-16 2016-01-27 天津医科大学眼科医院 间充质干细胞来源的外泌体的用途
WO2017123022A1 (fr) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
CN107106613A (zh) * 2014-11-07 2017-08-29 胞外体干细胞株式会社 用于成脂分化诱导、脂肪组织再生、皮肤美白或改善皱纹的包含干细胞来源外泌体的组合物
KR20180048431A (ko) * 2017-11-16 2018-05-10 (주)프로스테믹스 녹용 줄기세포 배양액을 포함하는 피부 재생용 기능성 조성물
CN108143750A (zh) * 2017-12-26 2018-06-12 湖北未来家园高科技农业股份有限公司 鹿胎盘外泌体的制备方法及应用
CN110037979A (zh) * 2019-04-25 2019-07-23 广州优理氏生物科技有限公司 含羊间充质干细胞外泌体冻干粉及其制备方法
CN110184235A (zh) * 2019-05-21 2019-08-30 大连英伦美焰生物科技有限公司 一种adsc外泌体及其制备方法与应用
CN110279648A (zh) * 2019-06-24 2019-09-27 广州远想生物科技有限公司 一种含外泌体的美容制剂及用途
CN110464671A (zh) * 2019-09-06 2019-11-19 天津珂芬迪斯生物医药科技有限公司 一种冻肽面霜及其制备方法
CN110840812A (zh) * 2019-11-27 2020-02-28 沣潮医药科技（上海）有限公司 胎体来源的外泌体在皮肤调节产品中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170044999A (ko) * 2015-10-16 2017-04-26 (주)프로스테믹스 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법
KR102037038B1 (ko) * 2017-01-11 2019-10-28 주식회사 스템랩 나노그를 도입한 양수 내 태아 유래 중간엽 줄기세포로부터 획득한 엑소좀 내 포함된 육모 촉진용 조성물의 제조방법
CN109464463A (zh) * 2018-11-15 2019-03-15 陕西九州生物医药科技集团有限公司 间充质干细胞外泌体抗皮肤表皮细胞氧化的特性及其制剂的制备方法
CN110129265A (zh) * 2019-05-20 2019-08-16 南京温博生物科技有限公司 一种脐带间充质干细胞外泌体、制备方法及在化妆品中的应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106613A (zh) * 2014-11-07 2017-08-29 胞外体干细胞株式会社 用于成脂分化诱导、脂肪组织再生、皮肤美白或改善皱纹的包含干细胞来源外泌体的组合物
CN105267240A (zh) * 2014-12-16 2016-01-27 天津医科大学眼科医院 间充质干细胞来源的外泌体的用途
WO2017123022A1 (fr) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Exosome dérivé de cellules souches contenant une quantité importante de facteurs de croissance
KR20180048431A (ko) * 2017-11-16 2018-05-10 (주)프로스테믹스 녹용 줄기세포 배양액을 포함하는 피부 재생용 기능성 조성물
CN108143750A (zh) * 2017-12-26 2018-06-12 湖北未来家园高科技农业股份有限公司 鹿胎盘外泌体的制备方法及应用
CN110037979A (zh) * 2019-04-25 2019-07-23 广州优理氏生物科技有限公司 含羊间充质干细胞外泌体冻干粉及其制备方法
CN110184235A (zh) * 2019-05-21 2019-08-30 大连英伦美焰生物科技有限公司 一种adsc外泌体及其制备方法与应用
CN110279648A (zh) * 2019-06-24 2019-09-27 广州远想生物科技有限公司 一种含外泌体的美容制剂及用途
CN110464671A (zh) * 2019-09-06 2019-11-19 天津珂芬迪斯生物医药科技有限公司 一种冻肽面霜及其制备方法
CN110840812A (zh) * 2019-11-27 2020-02-28 沣潮医药科技（上海）有限公司 胎体来源的外泌体在皮肤调节产品中的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307851A (zh) * 2021-06-11 2021-08-27 北京戴域生物技术有限公司 一种改善皮肤生理特性的活性肽与间充质干细胞外泌体在药品或化妆品中的应用

Also Published As

Publication number Publication date
CN110840812A (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
WO2021104214A1 (fr) Utilisation d'un exosome dérivé d'une carcasse dans un produit de régulation de la peau
CN111053716B (zh) 一种茯茶提取物在制备皮肤调节产品中的用途
US20230338425A1 (en) Novel use of milk exosomes
US8709511B2 (en) External preparation composition for skin comprising ginseng flower or ginseng seed extracts
KR101713357B1 (ko) 오미자 펩티드 추출물을 포함한 여드름 치료용 화장 조성물
US9282759B2 (en) Composition including an unsaponifiable fraction
US10688142B2 (en) Methods of treatment using a lipid extract of Passiflora seeds concentrated in its unsaponifiable fraction
CN102647920B (zh) 大穗金合欢种子提取物和含有大穗金合欢种子提取物的组合物
US10206861B2 (en) Compositions containing natural extracts and use thereof for skin and hair
CN103379910B (zh) 白花菜地上部分提取物及包含其的化妆品、皮肤病学或药物组合物
KR20190005369A (ko) 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물
KR101906604B1 (ko) 동부 종자 추출물 및 이를 함유한 조성물
CN102421412B (zh) 含有日本扁柏多糖的皮肤外用组合物
KR102343112B1 (ko) 기능성 펩타이드, 아미노산, 캘러스 추출물 및 발효물을 포함하는 항노화 조성물
CN106794136A (zh) 丹参提取物和烟酸和/或烟酰胺的组合产品的去糖基化作用
KR20130088997A (ko) 생캐비어 추출물 및 발효추출물을 이용한 육모, 발모, 탈모방지 및 두피 개선용 화장료 조성물
EP3434256B1 (fr) Compositions à base de plantes pour usage topique
AU2017425084B2 (en) Topical herbal compositions
JP7504423B2 (ja) メラニン生成抑制剤、表皮ターンオーバー促進剤、及び抗酸化遺伝子発現促進剤
CA3005842C (fr) Compositions contenant des extraits naturels et utilisation connexe pour la peau et les cheveux
JP2017088539A (ja) セラミド産生促進剤
HK1192152B (en) Novel anti-redness active agent and compositions comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20893463

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20893463

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 27/09/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20893463

Country of ref document: EP

Kind code of ref document: A1